Alligator Bioscience to attend ASCO 2025 Annual Meeting
Lund, Sweden, 12 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) is pleased to announce that data from its OPTIMIZE-1 clinic ...
Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer
Top-line readout demonstrates Objective Response Rate of 40.4%, meeting primary endpoint and confirming the benefit of mitazalimab in combin ...
Alligator Bioscience Granted New Composition of Matter Patent in Europe for Mitazalimab
New patent expands protection for mitazalimab in Europe Patent protects composition of matter for mitazalimab until 2038 (including potentia ...
Alligator Bioscience Presents New Data Demonstrating Durable Response and Encouraging Anti-Tumor Activity of Lead Asset Mitazalimab
Clinical and preclinical data from three presentations further demonstrate mitazalimab's ability to activate the immune system and enha ...
Alligator Bioscience to Present its CD40 Program at the 3rd Annual Tumor Myeloid-Directed Therapies Summit in July 2023
Presentation highlights very promising interim efficacy analysis from mitazalimab OPTIMIZE-1 Phase 2 study in pancreatic cancer Latest analy ...
Phase 2 results indicate durability of response for Alligator’s CD40 agonist
BioStock interview with Alligator CMO, Sumeet Ambarkhane. Following the second round of interim results from OPTIMIZE-1, the phase 2 trial w ...
Alligator Bioscience Announces Positive Second Interim Efficacy Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer
Continued follow-up on the futility analysis cohort (23 patients) showed deepening of tumor responses and an increase in Objective Response ...
Alligator Bioscience to Host Virtual Key Opinion Leader Event on Mitazalimab Latest Interim Phase 2 Data in 1st Line Metastatic Pancreatic Cancer
June 27, 2023 – 9:00 AM ET / 3:00 PM CET Featuring Dr. Zev Wainberg from UCLA Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) ...
Alligator Bioscience to Present Latest Clinical Data from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer at ASCO Annual Meeting 2023
Mitazalimab achieved 52% Objective Response Rate when combined with mFOLFIRINOX in 1st line pancreatic cancer and passed the futility analys ...